Long-term cardiovascular mortality among middle-aged men with gout

Archives of Internal Medicine

Volumn 168, Issue 10, 2008, Pages 1104-1110

  Krishnan, Eswar ^a,d   Svendsen, Kenneth ^b   Neaton, James D ^b   Grandits, Greg ^b   Kuller, Lewis H ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; DIURETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; FOLLOW UP; GOUT; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL;

ADULT; ARTHRITIS, GOUTY; CARDIOVASCULAR DISEASES; FOLLOW-UP STUDIES; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; TIME FACTORS; URIC ACID;

EID: 44349151051     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.10.1104     Document Type: Article

References (34)

1. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42(3):257-267.
2. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118(8):816-826.
3. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41(3):237-242.
4. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-2696.
5. Darlington LG, Slack J, Scott JT. Vascular mortality in patients with gout and in their families. Ann Rheum Dis. 1983;42(3):270-273.
6. Gelber AC, Klag MJ, Mead LA, et al. Gout and risk for subsequent coronary heart disease: the Meharry-Hopkins Study. Arch Intern Med. 1997;157(13):1436-1440.
7. Yü T, Talbott JH. Changing trends of mortality in gout. Semin Arthritis Rheum. 1980;10(1):1-9.
8. Janssens HJ. The Dutch College of General Practitioners' "Gout" Standard: a response from general practitioners [in Dutch]. Ned Tijdschr Geneeskd. 2002;146(7):292-294.
9. Chen SY, Chen CL, Shen ML. Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study. Clin Rheumatol. 2007;26(3):308-313.
10. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900.
11. Multiple Risk Factor Intervention Trial Group. Statistical design considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J Chronic Dis. 1977;30(5):261-275.
12. Kanellis J, Kang D, Feig F, Johnson R. Asymptomatic hyperuricemia. In: Wortmann RL, Schumacher HR, Becker MA, Ryan LM, eds. Crystal Induced Arthropathies: Gout, Pseudogout and Hydroxyapatite-Associated Syndromes. New York, NY: Taylor & Francis Group; 2006:83.
13. Mikkelsen WM. Epidemiology of hyperuricemia and gout. In: Smyth CJ, Hollers VM, eds. Gout, Hyperuricemia and Other Crystal-Associated Arthropathies. New York, NY: Marcel Dekker Inc; 1999:107-119.
14. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900.
15. Wentworth DN, Neaton JD, Rasmussen WL. An evaluation of the Social Security Administration master beneficiary record file and the National Death Index in the ascertainment of vital status. Am J Public Health. 1983;73(11):1270-1274.
16. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18.
17. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA. 1997;277(16):1293-1298.
18. De Muckadell OB, Gyntelberg F. Occurrence of gout in Copenhagen males aged 40-59. Int J Epidemiol. 1976;5(2):153-158.
19. Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys. 1999;372(2):285-294.
20. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584-C596.
21. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88(6):1785-1792.
22. Tsutsumi Z, Moriwaki Y, Takahashi S, Ka T, Yamamoto T. Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta. 2004;339(1-2):117-122.
23. Shemesh J, Morag-Koren N, Goldbourt U, et al. Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patients. J Hypertens. 2004;22(3):605-610.
24. Santos RD, Nasir K, Orakzai R, Meneghelo RS, Carvalho JA, Blumenthal RS. Relation of uric acid levels to presence of coronary artery calcium detected by electron beam tomography in men free of symptomatic myocardial ischemia with versus without the metabolic syndrome. Am J Cardiol. 2007;99(1):42-45.
25. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7-13.
26. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421-426.
27. Coutinho TA, Turner ST, Peyser PA, Bielak LF, Sheedy PF II, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20(1):83-89.
28. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39-42.
29. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27(10):1174-1181.
30. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23(12):1835-1839.
31. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998;19(12):1814-1822.
32. Olexa P, Olexová M, Gonsorcík J, Tkác I, Kisel'ová J, Olejníková M. Uric acid - a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr. 2002;114(5-6):211-215.
33. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991;34(2):141-145.
34. Dalbeth N, Haskard DO. Mechanisms of inflammation in gout. Rheumatology (Oxford). 2005;44(9):1090-1096.